260 related articles for article (PubMed ID: 28005176)
1. The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature.
Jarius S; Eichhorn P; Franciotta D; Petereit HF; Akman-Demir G; Wick M; Wildemann B
J Neurol; 2017 Mar; 264(3):453-466. PubMed ID: 28005176
[TBL] [Abstract][Full Text] [Related]
2. Frequency of an intrathecal IgM synthesis and MRZ reaction in children with MS.
Chen S; A B; Koukou G; Wendel EM; Thiels C; Baumann M; Lechner C; Blaschek A; Della Marina A; Classen G; Stüve B; Kauffmann B; Kapanci T; Mayer B; Otto M; Rostásy K
Eur J Paediatr Neurol; 2024 May; 50():51-56. PubMed ID: 38636242
[TBL] [Abstract][Full Text] [Related]
3. HLA Associations of Intrathecal IgG Production against Specific Viruses in Multiple Sclerosis.
Neidhart S; Vlad B; Hilty M; Högelin KA; Ziegler M; Berenjeno-Correa E; Reichen I; Stridh P; Jelcic I; Khademi M; Kockum I; Sospedra M; Al Nimer F; Martin R; Jelcic I
Ann Neurol; 2024 Jun; 95(6):1112-1126. PubMed ID: 38551149
[TBL] [Abstract][Full Text] [Related]
4. Frequency of an intrathecal IgM synthesis and MRZ reaction in children with MS.
Bigi S
Eur J Paediatr Neurol; 2024 May; 50():i. PubMed ID: 38782676
[No Abstract] [Full Text] [Related]
5. The MRZ reaction in primary progressive multiple sclerosis.
Hottenrott T; Dersch R; Berger B; Rauer S; Huzly D; Stich O
Fluids Barriers CNS; 2017 Feb; 14(1):2. PubMed ID: 28166789
[TBL] [Abstract][Full Text] [Related]
6. Deep gray matter atrophy in neuromyelitis optica spectrum disorder and multiple sclerosis.
Hyun JW; Park G; Kwak K; Jo HJ; Joung A; Kim JH; Lee SH; Kim S; Lee JM; Kim SH; Kim HJ
Eur J Neurol; 2017 Feb; 24(2):437-445. PubMed ID: 28009104
[TBL] [Abstract][Full Text] [Related]
7. Computational modeling of brain pathologies: the case of multiple sclerosis.
Pappalardo F; Rajput AM; Motta S
Brief Bioinform; 2018 Mar; 19(2):318-324. PubMed ID: 28011755
[TBL] [Abstract][Full Text] [Related]
8. Acute disseminated encephalomyelitis in China, Singapore and Japan: a comparison with the USA.
Koelman DL; Benkeser DC; Xu Y; Neo SX; Tan K; Katsuno M; Sobue G; Natsume J; Chahin S; Mar SS; Venkatesan A; Chitnis T; Hoganson GM; Yeshokumar AK; Barreras P; Majmudar B; Carone M; Mateen FJ
Eur J Neurol; 2017 Feb; 24(2):391-396. PubMed ID: 28009079
[TBL] [Abstract][Full Text] [Related]
9. The role of B cells in multiple sclerosis: more than antibodies.
Funaro M; Messina M; Shabbir M; Wright P; Najjar S; Tabansky I; Stern JN
Discov Med; 2016 Nov; 22(122):251-255. PubMed ID: 28009967
[TBL] [Abstract][Full Text] [Related]
10. Antibodies from multiple sclerosis patients preferentially recognize hyperglucosylated adhesin of non-typeable Haemophilus influenzae.
Walvoort MT; Testa C; Eilam R; Aharoni R; Nuti F; Rossi G; Real-Fernandez F; Lanzillo R; Brescia Morra V; Lolli F; Rovero P; Imperiali B; Papini AM
Sci Rep; 2016 Dec; 6():39430. PubMed ID: 28008952
[TBL] [Abstract][Full Text] [Related]
11. Causes of death in critically ill multiple sclerosis patients.
Karamyan A; Brandtner H; Grinzinger S; Chroust V; Bacher C; Otto F; Reisp M; Hauer L; Sellner J
Acta Neurol Scand; 2017 Oct; 136(4):305-309. PubMed ID: 28008594
[TBL] [Abstract][Full Text] [Related]
12. [
Raffel J; Sridharan S; Nicholas R
Ann Neurol; 2017 Feb; 81(2):323-324. PubMed ID: 28019656
[No Abstract] [Full Text] [Related]
13. High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes.
Beh SC; Kildebeck E; Narayan R; Desena A; Schell D; Rowe ES; Rowe V; Burns D; Whitworth L; Frohman TC; Greenberg B; Frohman EM
J Neurol Sci; 2017 Jan; 372():187-195. PubMed ID: 28017209
[TBL] [Abstract][Full Text] [Related]
14. Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet?
Dahdaleh M; Alroughani R; Aljumah M; AlTahan A; Alsharoqi I; Bohlega SA; Daif A; Deleu D; Inshasi J; Karabudak R; Sahraian MA; Taha K; Yammout BI; Zakaria M
Int J Neurosci; 2017 Oct; 127(10):944-951. PubMed ID: 28029270
[TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis: Is there a safe time to discontinue therapy in MS?
Freedman MS
Nat Rev Neurol; 2016 Dec; 13(1):10-11. PubMed ID: 28028316
[No Abstract] [Full Text] [Related]
16. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
17. Cognitive impairment and structural brain changes in patients with clinically isolated syndrome at high risk for multiple sclerosis.
Hynčicová E; Vyhnálek M; Kalina A; Martinkovič L; Nikolai T; Lisý J; Hort J; Meluzínová E; Laczó J
J Neurol; 2017 Mar; 264(3):482-493. PubMed ID: 28028623
[TBL] [Abstract][Full Text] [Related]
18. Network-based analysis of differentially expressed genes in cerebrospinal fluid (CSF) and blood reveals new candidate genes for multiple sclerosis.
Safari-Alighiarloo N; Rezaei-Tavirani M; Taghizadeh M; Tabatabaei SM; Namaki S
PeerJ; 2016; 4():e2775. PubMed ID: 28028462
[TBL] [Abstract][Full Text] [Related]
19. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro.
Takeshita Y; Obermeier B; Cotleur AC; Spampinato SF; Shimizu F; Yamamoto E; Sano Y; Kryzer TJ; Lennon VA; Kanda T; Ransohoff RM
Neurol Neuroimmunol Neuroinflamm; 2017 Jan; 4(1):e311. PubMed ID: 28018943
[TBL] [Abstract][Full Text] [Related]
20. Increased levels of cell-free mitochondrial DNA in the cerebrospinal fluid of patients with multiple sclerosis.
Varhaug KN; Vedeler CA; Myhr KM; Aarseth JH; Tzoulis C; Bindoff LA
Mitochondrion; 2017 May; 34():32-35. PubMed ID: 28017684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
